Hemispherx recently announced an important new step in its efforts to develop Ampligen as a powerful cancer-fighting therapy. The company announced the start at the UPMC Hillman Cancer Center in Pittsburgh, PA of a new clinical study supported by a major pharma company that will combine our company’s Ampligen with a powerful anti-PD-1 immunotherapy for the treatment of recurrent, platinum-sensitive, ovarian cancer.
The study will enroll up to 45 participants and be conducted at UPMC, which is sponsoring the study, by Robert Edwards, MD, director of the Ovarian Cancer Program at UPMC Magee Womens Hospital. Over the past year, Hemispherx has produced 16,000 vials of Ampligen, including all of the supply of Ampligen needed for this clinical trial. Hemispherx shipped Ampligen for the clinical trial to UPMC on January 29, 2019 and the first subject was enrolled.
“We believe this clinical study at UPMC is an important step in Hemispherx’ overall clinical plan in immuno-oncology and just one of the major milestones we have recently announced,” said Hemispherx CEO Thomas K. Equels.
See the full announcement on our Investor Relations page. Go to ClinicalTrials.gov to read all about the study.